Tools

Which psychedelic therapy might fit you?

A short, client-side decision tree that takes your goals, medical considerations, and legal constraints and suggests which therapy the evidence and access landscape supports exploring first. Not medical advice.

Depression treatment path

A practical next-step guide for treatment-resistant depression: compare Spravato, IV/IM ketamine, at-home ketamine, psilocybin trials, and Oregon/Colorado psilocybin services by legality, insurance, evidence, and what to ask at the first appointment.

At-home ketamine safety checklist

A safety-first guide to what is actually available at home: compounded oral/sublingual ketamine via telehealth, why Spravato is never take-home, what remote integration can and cannot do, and when at-home treatment is the wrong starting point.

Find a ketamine therapy provider

Curated directory of US ketamine therapy providers — at-home telehealth programs, in-clinic IV/IM infusion networks, and the Spravato (esketamine) REMS network — with vetting guidance.

Find a psychedelic-integration therapist

A curated meta-directory of the established psychedelic-therapist training programs (Fluence, CIIS, Polaris, IPI, Naropa, Sage, MAPS) whose alumni directories are the credible starting points.

Find a legal psychedelic retreat

Oregon Measure 109 and Colorado Prop 122 licensed service centers, plus the more medically-structured international operators for ayahuasca, ibogaine, and 5-MeO-DMT. Includes a retreat vetting checklist.

Legal psilocybin booking checklist

Step-by-step checklist for booking legal psilocybin services: verify Oregon or Colorado licenses, distinguish legal service centers from decriminalized possession, estimate total cost, screen facilitators, and plan preparation and integration.

Psychedelic Legalization Tracker

A running, auto-updated log of psychedelic legalization moves — new laws, decriminalizations, reschedulings, trial funding, and court rulings across US states and other countries, each linked to its source.

Psychedelic legal status by US state

Plain-English reference for where each state stands on therapeutic access, decriminalization, and active legislation. Filterable by reform type.

Psychedelic Legal Status Map of the United States

National overview of where every US state stands on psilocybin, MDMA, DMT, ibogaine, and ketamine. Four-tier ranking, clickable state grid, and 2026 reform watchlist.

Find Psychedelic Clinical Trials: How to Volunteer

How to find and apply for psychedelic clinical trials: psilocybin, MDMA, ibogaine, DMT, and ketamine. Registry links, institution-specific portals, eligibility criteria, what participation involves, and how participants are protected.

Ceremony readiness quiz

A 12-question self-assessment that scores your readiness for a psychedelic ceremony across medical, psychological, logistical, and integration dimensions. Not a clearance, not medical advice.

Trauma trigger to healing map

Pick a common trigger (criticism, abandonment, conflict, shame) and see the four F's response it usually maps to, what wound it points to, and the integration practices that support healing.

Psychedelic medication safety checker

An interactive screener: enter your prescriptions and supplements and see typical clinical-trial washout windows and the high-risk combinations. Educational only — always coordinate with your prescriber.

Compass Pathways’ Psilocybin Durability Data: Implications for U.S. Depression Treatment Policy

Compass Pathways has released new data on the durability of psilocybin therapy for depression, a key milestone for regulatory approval and insurance coverage. This analysis examines the findings, their implications, and the next challenges for clinical adoption.

Sep 15, 2026

USC Launches Clinical Study on Meditation in Psychedelic Therapy

USC is initiating a clinical trial to assess the impact of meditation on psychedelic therapy outcomes, aiming to inform best practices and future training standards. The study highlights growing academic focus on optimizing set and setting in psychedelic interventions.

Sep 15, 2026

FDA’s 2026 Hearing Sets New Standards for Psychedelic Therapies

The FDA’s 2026 public hearing on psychedelic therapy standards will shape regulatory pathways, clinical trial design, and commercialization, affecting researchers, clinicians, and industry stakeholders across the U.S.

Sep 15, 2026

FDA Issues Regulatory Framework for Psychedelic Drug Sponsors

The FDA's new regulatory framework for psychedelic drug sponsors provides clear guidance for clinical development, aiming to reduce uncertainty and accelerate research, but also introduces new compliance demands and unresolved challenges.

Sep 15, 2026

FDA Hears Veterans' Perspectives on Psychedelic PTSD Therapy

At a September 2026 FDA hearing, Jacksonville veterans shared experiences with psychedelic-assisted PTSD therapy, highlighting patient needs and shaping future regulatory and research pathways for these emerging treatments.

Sep 14, 2026